Dr. Ashley's primary research focus is laboratory based, investigating the role of immunotherapy as a novel approach to the treatment of tumors of the central nervous system (CNS). Since beginning his appointment at the faculty level at Duke in August of 1995 his activities have centered on two main areas of investigation. The first involves both in vivo and in vitro studies of the use of molecular therapeutics to target a CNS tumor associated antigen. The second area of interest comprises a detailed analysis of the role of TGF beta, a protein messenger produced by tumors of the CNS, both in the pathogenesis of disease and as a possible target for immunotherapy.
In addition to his laboratory role Dr. Ashely is involved in the design and application of a variety of clinical research protocols in the treatment of children with malignant brain tumors.
Education and Training
- Royal Australian College of Physicians, F.R.A.C.P. 1993
- University of Melbourne (Australia), M.B.B.S. 1994
- University of Melbourne (Australia), Ph.D. 1998
Selected Grants and Awards
- Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine Efficacy
- LGG-14C03: A Phase III study comparing two carboplatin containing regimens for children and young adults with previously untreated low grade glioma
- A Randomized, Multicenter, Phase 2 Study of PVSRIPO alone or in combination with Lomustine
- Poliovirus-Instigated APC Responses Against BRaf(V600E) for Pediatric Brain Tumor Immunotherapy
- Recombinant Attenuated Poliovirus Immunization Vectors Targeting H3.3(K27M) in DIPG
- SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma